新冠疫苗接种35个热门核心问题详细解答(2020.1.24更新)

2021-01-24 MedSci原创 MedSci原创

阻断新冠病毒最好的办法就是疫苗。在疫苗接种稳步推进的过程中,人们可能会有这样或那样的疑问,比如要不要接种,什么疫苗更好,是不是安全,会不会产生抗体等等。

阻断新冠病毒最好的办法就是疫苗。在疫苗接种稳步推进的过程中,人们可能会有这样或那样的疑问,比如要不要接种,什么疫苗更好,是不是安全,会不会产生抗体等等。

下面一一为您解答!在前面新冠疫苗接种30个热门核心问题详细解答(2020.12.31更新),基础上,进一步完善和补充,后续梅斯医学仍然不断完善问题,帮助大家解疑释惑!

01. 新冠疫苗来了,到底要不要打?

要!一方面我国几乎所有人都没有针对新冠病毒的免疫力,对新冠病毒是易感的,感染发病后,有的人还会发展为危重症,甚至造成死亡。接种疫苗后,一方面绝大部分人可以获得免疫力;另一方面,通过有序接种新冠病毒疫苗,可在人群中逐步建立起免疫屏障,阻断新冠肺炎的流行。

02. 开展新冠疫苗紧急接种重点人群包括哪些?

本次紧急接种主要涉及感染新冠风险较高的重点岗位人员。涉及——

  进口冷链物流相关人员

  隔离场所工作人员

  入境人员闭环管理从业人员

  海关边检人员

  内地籍跨境司机及接驳司机

  医疗卫生人员

  基层防疫人员

  公共交通从业人员

  因公因私出国工作及学习人员

03. 接种对象有哪些情况应暂缓接种新冠疫苗?

目前阶段,以下情况建议暂缓接种新冠疫苗:

以下10种人群基本都不能打疫苗!

(1)、对疫苗中任何成分过敏者,既往发生过疫苗严重过敏反应者,如急性过敏反应、荨麻疹、皮肤湿疹、呼吸困难、血管神经性水肿或腹痛者;

(2)、发热者、患急性疾病、严重慢性疾病、处于慢性疾病的急性发病期者;

(3)、妊娠期妇女和哺乳期妇女,接种3个月内有生育计划;

(4)、有惊厥、癫痫、脑病或精神疾病史或家族史者;患未控制的癫痫和其他进行性神经系统疾病者,有格林巴利综合症病史者;

(5)、已被诊断为患有先天性或获得性免疫缺陷、HIV感染、淋巴瘤、白血病或其他自身免疫疾病;

(6)、已知或怀疑患有严重呼吸系统疾病、严重心血管疾病、肝肾疾病、恶性肿瘤者;

(7)、使用抗肿瘤药物等免疫调节剂者;

(8)、有新冠病毒感染史者;

(9)、已经接种过其他疫苗患者不建议同时接种两种疫苗,最好能与其他疫苗相隔至少两周以上,尽量减少非预期的相互影响。

(10)、临床医师或接种工作人员认为不适合接种者(例如最近吃了某种抗生素,可能会产生相互作用的)。

04. 目前新冠疫苗,有哪几种?哪个最好?

目前全球新冠疫苗的研发有数百家单位,主要集中在几条技术路线上,包括灭活疫苗、基因重组疫苗、载体疫苗(包括腺病毒载体、减毒流感病毒载体)、核酸疫苗(mRNA疫苗、DNA疫苗)。

这5条技术路线,不能简单说哪条技术路线更好,要评价一个疫苗,一定要综合考虑到它的安全性、有效性、可及性、可负担性,这才是对一个疫苗的科学评价。

从目前的数据来看,国药生产的新冠灭活疫苗对由新冠病毒感染引起的疾病(COVID-19)的保护效力为79.34%,中和抗体转阳率为99.52%,对中重症的预防有效率为100%。科兴生物的灭活病毒疫苗CoronaVac人群保护力为78%(在国际上三个国家的临床研究结果)。美国辉瑞与莫德纳的mRNA疫苗效果约为95%,优于中国灭活疫苗,但是,从目前的全球接种来看,安全性可能比不上国内的灭活疫苗。

目前复星引进的 辉瑞的mRNA疫苗,最快也需要到今年上半年才可能进入中国。因此,考虑到现有防疫需要,只要是出于防病的目的,任何工艺的疫苗对于非禁忌症人群来说都是可以接受的。

05. 本次国内接种的是什么疫苗?

本次使用的是全病毒灭活疫苗,系通过化学等方法使新冠病毒失去感染性和复制力,同时保留能引起人体免疫应答活性而制备成的疫苗。

灭活疫苗的优势是传统经典的疫苗制备方式,属于成熟、可靠、经典的疫苗研发手段。

相对于其他技术路线而言,灭活疫苗研发平台成熟、生产工艺稳定、质量标准可控、保护效果良好,研发速度快,且易于规模化生产,具有国际通行的安全性和有效性评判标准。

06. 新冠疫苗打几针?

推荐免疫程序为2针,期间至少间隔14天,接种部位为上臂三角肌。随意调整免疫程序可能影响安全性、免疫应答效果和免疫持久性。

目前接种新冠病毒疫苗需要打两针,有3种接种方式,分别是0—0(两支是同时接种,即一只胳膊一针);0—14(先打一针,间隔14天再打一针);0—28(先打一针,间隔28天再打一针)。

07. 错过第二剂的接种时间或延迟接种如何补种?

目前尚未获得不同免疫程序的临床研究数据,因此尚未确定2剂新冠灭活疫苗间最大间隔。如错过接种时间,建议尽快补齐相应剂次。

08. 两针不同新冠疫苗可以互换吗?

针对这种情况,建议使用同一厂家的新冠疫苗完成全程免疫。

09. 是否需要检查产生抗体?如何检查抗体,如果为阴性需要补种吗?

不建议!由于检测方法学和相关试剂灵敏度不同,结果可能无法显示真实信息,结合疫苗研发机构的实验室检测结果,可推测中和抗体阳转率超过90%,

因此除有特殊需求群体外无需专门进行抗体检测,也暂不推荐对于自行检测抗体结果阴性人群进行补种。

10. 新冠疫苗能不能和HPV疫苗、流感疫苗、狂犬疫苗等其他疫苗一起接种?

理论上说,新冠疫苗与流感疫苗间应该不具有交叉反应,而且目前国内所有可及的新冠疫苗均为灭活疫苗,相对来说安全性也较好。

不过,对于新冠疫苗这个疫苗家族新成员,因此建议在技术指南等文件明确之前,暂不建议与其他疫苗同时接种。但是有如疑似狂犬病暴露者需接种狂犬疫苗、其他外伤需接种破伤风疫苗者,应优先接种。

14天内接种其他灭活疫苗,28天内接种减毒活疫苗者,暂缓接种新冠疫苗。

11. 新冠疫苗在这么短时间研发成功,接种是否安全?

新冠疫苗和其他疫苗一样,在上市前都经过动物实验、人体预测试实验、人群Ⅰ/Ⅱ期、Ⅲ期临床试验,疫苗安全性得到了多次验证。

12. 接种新冠疫苗后可能出现哪些不良反应?

与其他任何疫苗一样,接种新冠灭活疫苗可能会出现一些常见的一般反应,如接种部位酸胀、红肿、疼痛、瘙痒等;

极少数人因个体差异可能会出现发热、乏力、恶心、头痛、肌肉酸痛等,一般不需处理,2-3天后大多可自行恢复。目前尚未监测到发生与疫苗相关的严重不良反应。

由于疫苗所含成分的特异性属性有可能诱发过敏性反应,这是疫苗本身特性之一,由此产生的不良反应,不代表疫苗本身的质量和安全性存在问题。

13. 接种新冠疫苗后感冒发烧了是怎么回事?

这可能是偶合症。所谓偶合症,是指受种者在接种时正处于某种疾病的潜伏期或者前驱期,接种后巧合发病。偶合症不是由疫苗的固有性质引起的,即偶合症的发生与疫苗本身无因果关联。

14. 接种新冠疫苗前后有哪些注意事项?

接种新冠灭活疫苗前,接种医生会询问健康状况,请如实告知相关信息。接种完成后,需现场留观30分钟,接种当日注射部位保持干燥并注意个人卫生,适当安排休息。

接种后一周内避免接触个人既往已知过敏物及常见致敏原,尽量不饮酒、不进食辛辣刺激或海鲜类食物,建议清淡饮食、多喝水。

15. 出现不良反应,应该如何处理?

目前接种数据显示,一般接种后24小时内,注射部位可能出现疼痛、触痛、红肿和瘙痒,多数情况下于2天—3天内自行消失;接种疫苗后可能出现一过性发热反应,短期内自行消失,不需处理;如果症状较重或无法自行评判严重程度,应及时就医处理。

16. 接种新冠疫苗后如出现严重的不良反应怎么报告?

根据既往的经验,一般接种疫苗后严重的不良反应会在接种后30分钟内出现,请及时告知接种点医生。如离开接种场所以后出现有严重的反应,怀疑与接种有关,应该及时向接种点的医生报告。

17. 接种新冠疫苗后多久可以产生抗体?

临床研究表明——接种新冠灭活疫苗第一剂后7天普遍开始产生抗体,14-28天抗体阳性率约60%-90%;接种第二剂28天后抗体阳性率均达90%以上,并形成持续保护。

18. 接种新冠疫苗后是否就不会得病?

本次接种的新冠灭活疫苗Ⅰ/Ⅱ期临床试验揭盲结果综合显示,疫苗接种后均产生高滴度免疫应答,中和抗体阳转率达90%以上。

在全球多个国家进行的Ⅲ期临床试验,疫苗有效性进一步得到验证。但需注意的是,到目前为止,任何疫苗的保护效果都不能达到100%。少数人接种后未产生保护力,或者仍然发病,与疫苗本身特性和受种者个人体质均有关。

19. 新冠疫苗保护效果可以维持多久?

目前新冠病毒发现的时间还不到一年,对于新冠灭活疫苗的免疫持久性也仍在持续观察中。目前证据提示,疫苗保护期可以达到至少半年以上。

20. 接种新冠疫苗后,核酸检测会呈阳性吗?

不会。核酸检测的是新冠病毒抗原,本疫苗为灭活疫苗,是一种“被杀死”的病原微生物,已完全失去感染性和复制力,故接种后不会导致患新冠肺炎,也不会因接种疫苗使新冠病毒核酸检测呈阳性。

21. 接种新冠疫苗后还需做核酸检测吗?接种证明能否替代核酸检测报告?

接种疫苗可以在一定程度上降低感染风险,但任何疫苗的保护效果都不能达到100%,必要时仍应配合相关部门进行核酸检测。

22. 接种新冠疫苗后,出入境检查血清抗体呈阳性怎么办?

本次使用的是全病毒灭活疫苗,新冠灭活疫苗紧急接种者在国内外医学检查中,如遇血清抗体检测结果为阳性,核酸检测等其他检查结果为阴性,可声明已接种疫苗并出示接种证,以便相关机构鉴别诊断。因此,要注意保管和带好接种证明

23. 打了新冠疫苗,是不是还要继续戴口罩?

到目前为止,任何疫苗的保护效果都不能达到100%,少数人接种后仍可能不产生保护力或者发病。目前,人群免疫屏障尚未建立。因此,预防新冠病毒感染,不能把宝全押在疫苗上。

在人群免疫屏障没有建立起来之前,即使部分人群接种了疫苗,大家的防控意识和防控措施也不能放松。因此,接种疫苗后还是应该继续佩戴口罩,特别是在人员密集的场所;其他防护措施也同样需要继续保持,如注意手部卫生、通风、保持社交距离等。

  我们仍需牢记——

  “防疫三件套”:佩戴口罩、社交距离、个人卫生

  “防护五还要”:口罩还要戴、社交距离还要留、咳嗽喷嚏还要遮、双手还要经常洗、窗户还要尽量开

24. 个人可以将新冠疫苗带给海外的同事接种吗?

新冠灭活疫苗出入境有严格的审批程序,个人不得私自携带新冠灭活疫苗出境,否则,可能面临违反境内外法律等风险。

25. 普通公众何时可以开始接种疫苗?

根据国务院联防联控机制发布会介绍的情况,新冠疫情发生以后,我国布局了五条技术路线,推进疫苗研发。

到目前为止,按照世界卫生组织的统计,我们进入临床试验的疫苗、进入三期临床的疫苗,都处于全球第一方阵。

由于我国疫情较早得到控制,国内不具备开展三期临床试验的条件,所以我国五款进入三期临床试验的疫苗都是在国外开展的三期临床试验。目前国药中生疫苗正在药监中审查,相信在近期就会公布。大概率会通过审批,普通老百姓便可以进行接种。

26. 得过新冠肺炎,或是无症状感染者,还有必要接种新冠疫苗么?

虽然基于现有已发表信息,在包括中国香港、比利时、荷兰、美国等地通过基因测序的结果均发现再次感染现象,无法得出一次感染终身免疫的结论,

但一般来说,感染过传染病或无症状感染,均会产生相应的抗体,应该具有类似接种疫苗的保护作用,建议新冠肺炎康复者或无症状感染者不接种新冠疫苗。

27. 海鲜/鸡蛋/青霉素过敏可以接种新冠疫苗吗?

海鲜/鸡蛋/青霉素不是新冠疫苗任何一种成分,免疫程序中明确过敏个体并不是接种疫苗的特殊禁忌,因此可以考虑接种。

但是有过敏体质的人群,接种后,要注意观察,尤其是接种后的30分钟内需要留观。

28. 有某病(哮喘/风湿/糖尿病/手术)可以接种新冠疫苗吗?

目前用于紧急使用的新型冠状病毒灭活疫苗(Vero细胞)说明书中指出,个人患慢性疾病者慎用,慢性疾病急性发作者禁忌接种。

鉴于慢性病患者是新冠肺炎重症和死亡高危人群,需要对慢性病患者在非发作期接种新冠疫苗。

29. 病毒变异会对疫苗保护性有影响吗?

病毒基因突变是永恒的,病毒在人体内复制及传播过程中不断出现变异,是生物进化的自然现象。

现在新冠病毒虽然也发生了一定程度的变异,但根据世界卫生组织网站目前发布的信息,显示针对在英国和南非等国家出现的新冠病毒所发生的变异,没有证据表明现有的新冠病毒疫苗失效。新冠病毒疫苗是否会像流感疫苗一样每年接种,需要继续针对病毒变异对疫苗接种效果的影响和疫苗的保护持久性等方面开展研究。

30. 哪里可以接种新冠病毒疫苗?

接种单位一般都是设在辖区的卫生服务中心、乡镇卫生院或者二级以上综合医院。各地将及时公布辖区内的接种点、能够接种疫苗的单位,包括地点、服务时间。可以咨询所在的辖区地方卫生行政部门、或者疾病预防控制机构,关注相关信息发布平台。

31、新冠病毒疫苗怎么打,去哪儿打?

新冠病毒疫苗的接种都是在当地卫生健康行政部门批准的接种单位进行。通常情况下,接种单位设在辖区的卫生服务中心、乡镇卫生院或者综合医院。如果接种涉及一些重点对象比较集中的部门或企业,当地也会根据情况设立一些临时接种单位。

辖区卫生健康行政部门或者疾病预防控制机构也会按要求公布可以进行新冠病毒疫苗接种的接种单位,包括地点、服务时间,请大家关注相关信息发布平台。

大多数重点人群的接种,由重点人群所在的单位组织摸底、预约,并协助开展接种工作。对于前往中高风险国家或者地区工作、学习的个人,可关注当地新冠病毒疫苗接种的相关服务信息。

提醒:一定要按照接种单位通知的安排和提醒,比如要携带身份证,做好个人防护,主动提供身体情况等。

32、如何通过接种疫苗在人群中形成群体免疫?

不同传染病的传染力不一样,阻断传染病流行的人群免疫力水平也不一样。一般而言,传染病的传染力越强,则需要越高的人群免疫力。例如,麻疹和百日咳传染力较强,如果要阻断它们的流行,人群免疫力要达到90%-95%;而消灭天花和脊髓灰质炎,人群免疫力要达到80%以上。人群免疫力达到上述阈值,也就建立了阻断麻疹、百日咳、天花和脊髓灰质炎传播的免疫屏障。

人群免疫力跟疫苗保护效力和疫苗的接种率呈正比。因此,要达到足够的人群免疫力,需要有足够高的接种率,也就是绝大多数人都接种疫苗。反之,如果不接种的人比较多或大多数人不愿去接种,就形成不了牢固的免疫屏障,有传染源存在时,容易出现疾病的传播。

33、接种新冠病毒疫苗后是否需要检查抗体?

不建议,由于检测方法学和相关试剂灵敏度不同,结果可能无法显示真实信息,结合疫苗研发机构的实验室检测结果,可推测中和抗体阳转率超过90%,因此除有特殊需求群体外无需专门进行抗体检测,也暂不推荐对于自行检测抗体结果阴性人群进行补种。

34、南非新冠变异病毒有多厉害?我们将要打的疫苗还有用吗?

2020年12月18日,南非检测到一种新冠病毒变体——501Y.V2变体,该突变株含有K417N、E484K、N501Y三个关键突变,目前南非突变株已经传播至20个国家,我国也曾报道过该突变株境外输入的病例。据研究表明,南非新冠变异病毒影响到中和抗体的作用。mRNA疫苗接种对于南非毒株的中和活性可能会下降,但下降程度有限。

我们国家采用的是灭活疫苗技术,从目前的明确数据表明,中国国药疫苗对各种变异株都有预防作用。灭活疫苗免疫以后,对包括英国突变的毒株和以往全球分离到的大概八九株的不同的变异株都有中和效果。对南非相关的病毒的预防作用,确实需要进一步验证。因此,我国的新冠病毒灭活疫苗是广谱保护的,对来自全球不同地区的毒株都有很好的交叉中和。

35、癌症病人能不能打新冠疫苗?

目前没有科学的结论,不过一般认为接种是可以的。全球目前还没有很多癌症病人接种新冠疫苗的研究成果,不过之前有报道称有癌症病人感染了新冠病毒之后竟然痊愈了。

不过,癌症病人接种了疫苗的免疫效果还很难说,可能无法形成免疫力,这跟正常人的表现不一样。国外有些医生建议:如果癌症病人要接种疫苗,那么可以配合干扰素一起使用,提升疫苗效果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-02-08 Midas

    不建议查抗体?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 14647530m41(暂无昵称)

    已打针

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 Wlgank

    已打第一针

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 ms6000001242401176

    科学防控

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 ms2000000770930337

    全面

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 ms9000001555953711

    层次分明,很nice

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=923615, encodeId=cb629236156d, content=不建议查抗体?, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/20/dafb36f63f4241903de36c3d053babb8.jpg, createdBy=d367105945, createdName=Midas, createdTime=Mon Feb 08 10:36:17 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257925, encodeId=3429125e925ff, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Jan 26 08:00:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919533, encodeId=582991953365, content=已打针, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=665f5126189, createdName=14647530m41(暂无昵称), createdTime=Sun Jan 24 20:37:05 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919487, encodeId=134091948edf, content=已打第一针, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210209/c24ce6bb97bb4de0968e69be1f6d3ca4/93f7c058bb894fc39a47081bc5283bc1.jpg, createdBy=e3945412064, createdName=Wlgank, createdTime=Sun Jan 24 17:18:17 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919555, encodeId=d3df9195550b, content=科学防控, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4445454374, createdName=ms6000001242401176, createdTime=Sun Jan 24 22:19:47 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1029030, encodeId=613c1029030f3, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Jan 24 20:00:32 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919497, encodeId=cce991949e9d, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8bd5455325, createdName=ms2000000770930337, createdTime=Sun Jan 24 18:11:28 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919494, encodeId=9df891949410, content=层次分明,很nice, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05375455407, createdName=ms9000001555953711, createdTime=Sun Jan 24 18:02:27 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919484, encodeId=b73191948404, content=全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Jan 24 17:12:13 CST 2021, time=2021-01-24, status=1, ipAttribution=)]
    2021-01-24 lovetcm

    全面

    0

相关资讯

2021年1月18日全球新冠肺炎(COVID-19)疫情简报,确诊超9542万,国内青少年有望3月开学前接种新冠疫苗

Worldometers世界实时统计数据显示,截至北京时间2021年1月18日7时11分,全球累计确诊新冠肺炎(COVID-19)病例超过9542万例,新增496,012例,达到95,429,228例

2021年1月19日全球新冠肺炎(COVID-19)疫情简报,确诊超9596万,辉瑞和Moderna疫苗在多国出现严重不良反应

Worldometers世界实时统计数据显示,截至北京时间2021年1月18日7时31分,全球累计确诊新冠肺炎(COVID-19)病例超过9596万例,新增445,346例,达到95,964,755例

目前哪些国家订购了中国的新冠疫苗?全新摩洛哥批准紧急使用中国新冠疫苗

摩洛哥卫生部22日发布公报说,摩洛哥正式批准在摩紧急使用中国国药集团新冠灭活疫苗。

2021年1月15日全球新冠肺炎(COVID-19)疫情简报,确诊超9345万,死亡超200万,中美接种超1000万人次

Worldometers世界实时统计数据显示,截至北京时间2021年1月15日7时21分,全球累计确诊新冠肺炎(COVID-19)病例超过9345万例,新增694,559例,达到93,455,184例

NEJM: 强生公布腺病毒载体新冠疫苗Ad26.COV2.S早期临床结果,效果惊人

在已经进入3期临床开发阶段的在研新冠疫苗中,强生公司(Johnson & Johnson)开发的候选疫苗Ad26.COV2.S是少数计划通过

阿斯利康疫苗因产能受限,延迟向欧盟交付新冠疫苗

由于产量无法达到预期,英国阿斯利康制药公司将削减向欧洲联盟的新冠疫苗初始交付量,引发后者强烈不满。